Prof Christian Blank speaks to ecancer at ASCO 2024 about results from the phase III NADINA trial.

This trial evaluated neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma.

This is the first phase 3 trial that evaluates neoadjuvant immunotherapy against standard of care in melanoma.

Dr Blank notes that neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant treatment results in statistically significant improved event-free survival compared to adjuvant nivolumab and should be considered a new standard of care.